
Lonza Group
Price
Price
CHART BY
Historical dividends and forecast
The next dividend will be paid on 15.05.2025
CHART BY
Frequently asked questions
What is Lonza Group's market capitalization?
What is Lonza Group's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Lonza Group?
What are the analyst ratings and target price for Lonza Group's stock?
What is Lonza Group's revenue over the trailing twelve months?
Is Lonza Group paying dividends?
What is the EBITDA for Lonza Group?
What is the free cash flow of Lonza Group?
How many employees does Lonza Group have, and what sector and industry does it belong to?
What is the free float of Lonza Group's shares?
Financials
- Market Cap
- 41.04B
- EPS (TTM)
- $8.93
- Free Float
- 68.19M
- P/E ratio (TTM)
- 65.35
- Revenue (TTM)
- 6.57B
- EBITDA (TTM)
- 1.49B
- Free Cashflow (TTM)
- -108.00M
Pricing
- 1D span
- $646.87$653.17
- 52W span
- $511.49$683.30
Analyst Ratings
The price target is 665.52 and the stock is covered by 27 analysts.
Buy
22
Hold
5
Sell
0
Information
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment design, development, and manufacturing, with the ability to offer integrated drug substances to drug product solutions, including particle engineering and drug product packaging. The Cell and Gene segment develops, de-risk, commercializes, and scales their emerging therapies through its three business areas Cell and Gene Technologies, Bioscience, and Personalized Medicine. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.
- Employees
- 18,686
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- CH0013841017
- Primary Ticker
- LONN